BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 191413)

  • 1. Column separation of viral capsid antigen (VCA)-positive cells from VCA-negative cells in an Epstein-Barr virus (EBV)-producing lymphoid line,
    Dalianis T; Klein G; Andersson B
    Int J Cancer; 1977 Apr; 19(4):460-7. PubMed ID: 191413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein-Barr virus-associated antigens.
    Reedman BM; Hilgers J; Hilgers F; Klein G
    Int J Cancer; 1975 Apr; 15(4):566-71. PubMed ID: 166941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
    Fresen KO; zur Hausen H
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA.
    Dillner J; Kallin B; Ehlin-Henriksson B; Timar L; Klein G
    Int J Cancer; 1985 Mar; 35(3):359-66. PubMed ID: 2982749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between Epstein-Barr virus (EBV)-production and the loss of the EBV receptor/complement receptor complex in a series of sublines derived from the same original Burkitt's lymphoma.
    Klein G; Yefenof E; Falk K; Westman A
    Int J Cancer; 1978 May; 21(5):552-60. PubMed ID: 207646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of rabbit antibodies against the viral capsid antigen (VCA) of the Epstein-Barr virus (EBV).
    Vestergaard BF; Hesse J; Norrild B; Klein G
    Int J Cancer; 1978 Mar; 21(3):323-8. PubMed ID: 75856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
    Kurakata S; Ramos OF; Klein G; Klein E
    Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen.
    Kishishita M; Luka J; Vroman B; Poduslo JF; Pearson GR
    Virology; 1984 Mar; 133(2):363-75. PubMed ID: 6324457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplicity-dependent induction of viral capsid antigen in Raji cells superinfected with Epstein-Barr virus.
    Fujiwara S; Takada K; Yano S; Osato T
    Virology; 1983 Jul; 128(2):490-4. PubMed ID: 6310870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.
    Sairenji T; Reisert PS; Spiro RC; Connolly T; Humphreys RE
    J Exp Med; 1985 May; 161(5):1097-111. PubMed ID: 2580934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme-linked immunosorbent assay for the detection of Epstein-Barr virus-induced antigens and antibodies.
    Sternås L; Luka J; Kallin B; Rosén A; Henle W; Henle G; Klein G
    J Immunol Methods; 1983 Oct; 63(2):171-85. PubMed ID: 6311908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adenine arabinoside on Epstein-Barr virus in vitro.
    Coker-Vann M; Dolin R
    J Infect Dis; 1977 Mar; 135(3):447-53. PubMed ID: 191542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye.
    Sairenji T; Hinuma Y
    Int J Cancer; 1980 Sep; 26(3):337-42. PubMed ID: 6270005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle.
    Klein G; Clements G; Zeuthen J; Westman A
    Int J Cancer; 1976 Jun; 17(6):715-24. PubMed ID: 59708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of slides for Epstein-Barr virus diagnosis by indirect immunofluorescence].
    Pérez GR; Taborda MA; Toffi A; Palonsky M; Pagotto M; Gardiol DN; Giri AA
    Medicina (B Aires); 2005; 65(4):315-20. PubMed ID: 16193709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appearance of early and late components of Epstein-Barr virus-associated membrane antigen in Daudi cells superinfected with P3HR-1 virus.
    Sairenji T; Hinuma Y; Sekizawa T; Yoshida M
    J Gen Virol; 1978 Jan; 38(1):111-20. PubMed ID: 202665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybridization between a human epithelial line, infectable by Epstein-Barr virus, and Burkitt lymphoma lines: membrane properties, superinfectability, inducibility and tumorigenicity.
    Mitrani-Rosenbaum S; Ber R; Goldblum N; Povey S; Gamliel H; Ben-Bassat H
    Int J Cancer; 1982 Nov; 30(5):593-600. PubMed ID: 6295967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of n-butyrate on Epstein-Barr virus-carrying lymphoma lines.
    Anisimová E; Saemundsen AK; Roubal J; Vonka V; Klein G
    J Gen Virol; 1982 Jan; 58 Pt 1():163-71. PubMed ID: 6292341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
    Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
    Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV.
    Fresen KO; Cho MS; zur Hausen H
    Int J Cancer; 1978 Oct; 22(4):378-83. PubMed ID: 212377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.